Form 4: Cullinan Therapeutics CSO Jennifer Michaelson Sells 8,000 Shares

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of common stock on September 5, 2024, at a weighted average price of $18.09.

Summary

• On September 5, 2024, Jennifer Michaelson, the Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $18.09 per share.
• The transactions occurred at prices ranging from $17.79 to $18.55.
• Following the transaction, Michaelson directly owns 115,942 shares of Cullinan Therapeutics.
• The sale was conducted under a pre-arranged trading plan established on January 5, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, as it's a factual disclosure. The sale was conducted under a pre-arranged trading plan, which reduces the likelihood of it being driven by negative sentiment.

Industry Context

Insider sales are a common occurrence in publicly traded companies. They are often scrutinized by investors as they can provide insights into management's perspective on the company's future prospects. However, sales under pre-arranged trading plans (Rule 10b5-1) are generally viewed as less informative, as they are often established for personal financial planning reasons.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates